Carmot Therapeutics Stock
HealthTechCarmot Therapeutics is a developer of metabolic drugs designed to access therapeutic target spaces that are not typically reached by conventional small-molecule technologies. The company leverages its proprietary chemotype evolution technology for the rapid identification of innovative drugs through an evolutionary lead-identification paradigm. This enables physicians to effectively treat metabolic diseases, cancer, and inflammation.
5AM Ventures, Ponoi Capital, TCG Crossover Management, Michael J. Fox Foundation, Amgen, RA Capital Management, Millennium Management, National Science Foundation, Willett Advisors, Venrock, National Cancer Institute, Franklin Templeton, Deep Track Capital, Janus Henderson Investors, Horizons Ventures, QB3, The Column Group, Qualifying Therapeutic Discovery Project, Jerome Dahan, Frazier Lifesciences Acquisition.